CoChat
Sign Up
Cited by 57

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Endosomal trafficking in metabolic homeostasis and diseases

Gilleron, Jerome, Zeigerer, Anja·2023·Nature Reviews Endocrinology
DOI 10.1038/s41574-022-00737-9
Open this paper in CoChat — free account

Abstract

The global prevalences of obesity and type 2 diabetes mellitus have reached epidemic status, presenting a heavy burden on society. It is therefore essential to find novel mechanisms and targets that could be utilized in potential treatment strategies and, as such, intracellular membrane trafficking has re-emerged as a regulatory tool for controlling metabolic homeostasis. Membrane trafficking is an essential physiological process that is responsible for the sorting and distribution of signalling receptors, membrane transporters and hormones or other ligands between different intracellular compartments and the plasma membrane. Dysregulation of intracellular transport is associated with many human diseases, including cancer, neurodegeneration, immune deficiencies and metabolic diseases, such as type 2 diabetes mellitus and its associated complications. This Review focuses on the latest advances on the role of endosomal membrane trafficking in metabolic physiology and pathology in vivo, highlighting the importance of this research field in targeting metabolic diseases.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41574-022-00737-9

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Sub-domain dysfunction is associated with human disease.

    “Sub-domain dysfunction is associated with human disease, but our mechanistic understanding of its function remains poorly described.”

    From Mapping of endosomal proximity proteomes reveals Retromer as a hub for RAB GTPase regulation (2025) · cites this paper as [5]

  • Perturbed endosomal transport is a contributing factor and, in some cases, a causative factor in human diseases, including neurodegenerative and neurological, and metabolic syndromes and cardiovascular disease.

    “An increasing body of evidence points to perturbed endosomal transport being a contributing factor and, in some cases, a causative factor in human diseases, including neurodegenerative and neurological2–4, and metabolic syndromes and cardiovascular disease5.”

    From Mapping of endosomal proximity proteomes reveals Retromer as a hub for RAB GTPase regulation (2025) · cites this paper as [5]

  • Functional retrieval sub-domains are essential for development and homeostasis, and disease-associated sub-domain dysregulation is associated with human disease.

    “Analysis in cells and organisms have established the essential importance of functional retrieval sub-domains for development and homeostasis, and disease-associated sub-domain dysregulation is associated with human disease2–5.”

    From Mapping of endosomal proximity proteomes reveals Retromer as a hub for RAB GTPase regulation (2025) · cites this paper as [5]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 199

  1. Sattar, N. et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108, 414–419 (2003). · DOI · Paper page
  2. Noubiap, J. J. et al. Geographic distribution of metabolic syndrome and its components in the general adult population: a meta-analysis of global data from 28 million individuals. Diabetes Res. Clin. Pract. 188, 109924 (2022). · DOI
  3. Lillich, F. F., Imig, J. D. & Proschak, E. Multi-target approaches in metabolic syndrome. Front. Pharmacol. 11, 554961 (2020). · DOI
  4. Müller, T. D., Blüher, M., Tschöp, M. H. & DiMarchi, R. D. Anti-obesity drug discovery: advances and challenges. Nat. Rev. Drug Discov. 21, 201–223 (2022). · DOI · Paper page
  5. Shaffner, J., Chen, B., Malhotra, D. K., Dworkin, L. D. & Gong, R. Therapeutic targeting of SGLT2: a new era in the treatment of diabetes and diabetic kidney disease. Front. Endocrinol. 12, 749010 (2021). · DOI
  6. Filipovic, B. et al. The new therapeutic approaches in the treatment of non-alcoholic fatty liver disease. Int. J. Mol. Sci. https://doi.org/10.3390/ijms222413219 (2021). · DOI
  7. Tak, Y. J. & Lee, S. Y. Anti-obesity drugs: long-term efficacy and safety: an updated review. World J. Mens Health 39, 208–221 (2021). · DOI
  8. Cullen, P. J. & Steinberg, F. To degrade or not to degrade: mechanisms and significance of endocytic recycling. Nat. Rev. Mol. Cell Biol. 19, 679–696 (2018). · DOI · Paper page
  9. Villasenor, R., Kalaidzidis, Y. & Zerial, M. Signal processing by the endosomal system. Curr. Opin. Cell Biol. 39, 53–60 (2016). · DOI
  10. Villasenor, R., Nonaka, H., Del Conte-Zerial, P., Kalaidzidis, Y. & Zerial, M. Regulation of EGFR signal transduction by analogue-to-digital conversion in endosomes. Elife https://doi.org/10.7554/eLife.06156 (2015). · DOI
  11. Vazirani, R. P. et al. Disruption of adipose Rab10-dependent insulin signaling causes hepatic insulin resistance. Diabetes 65, 1577–1589 (2016). · DOI
  12. Zeigerer, A. et al. Regulation of liver metabolism by the endosomal GTPase Rab5. Cell Rep. 11, 884–892 (2015). · DOI
  13. Seitz, S. et al. Hepatic Rab24 controls blood glucose homeostasis via improving mitochondrial plasticity. Nat. Metab. 1, 1009–1026 (2019). · DOI
  14. Trelford, C. B. & Di Guglielmo, G. M. Molecular mechanisms of mammalian autophagy. Biochem. J. 478, 3395–3421 (2021). · DOI
  15. Papandreou, M. E. & Tavernarakis, N. Crosstalk between endo/exocytosis and autophagy in health and disease. Biotechnol. J. 15, e1900267 (2020). · DOI
  16. Buratta, S. et al. Lysosomal exocytosis, exosome release and secretory autophagy: the autophagic- and endo-lysosomal systems go extracellular. Int. J. Mol. Sci. https://doi.org/10.3390/ijms21072576 (2020). · DOI · Paper page
  17. Mayor, S., Parton, R. G. & Donaldson, J. G. Clathrin-independent pathways of endocytosis. Cold Spring Harb. Perspect. Biol. https://doi.org/10.1101/cshperspect.a016758 (2014). · DOI · Paper page
  18. Merrifield, C. J. & Kaksonen, M. Endocytic accessory factors and regulation of clathrin-mediated endocytosis. Cold Spring Harb. Perspect. Biol. 6, a016733 (2014). · DOI
  19. Maxfield, F. R. Role of endosomes and lysosomes in human disease. Cold Spring Harb. Perspect. Biol. 6, a016931 (2014). · DOI
  20. Mellman, I. & Yarden, Y. Endocytosis and cancer. Cold Spring Harb. Perspect. Biol. 5, a016949 (2013). · DOI
  21. Gilleron, J., Gerdes, J. M. & Zeigerer, A. Metabolic regulation through the endosomal system. Traffic https://doi.org/10.1111/tra.12670 (2019). · DOI
  22. Grant, B. D. & Donaldson, J. G. Pathways and mechanisms of endocytic recycling. Nat. Rev. Mol. Cell Biol. 10, 597–608 (2009). · DOI · Paper page
  23. Klip, A., McGraw, T. E. & James, D. E. Thirty sweet years of GLUT4. J. Biol. Chem. 294, 11369–11381 (2019). · DOI
  24. Hunter, T. Tyrosine phosphorylation: thirty years and counting. Curr. Opin. Cell Biol. 21, 140–146 (2009). · DOI
  25. Popovic, D., Vucic, D. & Dikic, I. Ubiquitination in disease pathogenesis and treatment. Nat. Med. 20, 1242–1253 (2014). · DOI
  26. Andreou, A. M. & Tavernarakis, N. SUMOylation and cell signalling. Biotechnol. J. 4, 1740–1752 (2009). · DOI
  27. Sanger, A., Hirst, J., Davies, A. K. & Robinson, M. S. Adaptor protein complexes and disease at a glance. J. Cell Sci. https://doi.org/10.1242/jcs.222992 (2019). · DOI
  28. Bonifacino, J. S. & Lippincott-Schwartz, J. Coat proteins: shaping membrane transport. Nat. Rev. Mol. Cell Biol. 4, 409–414 (2003). · DOI
  29. Koike, S. & Jahn, R. SNARE proteins: zip codes in vesicle targeting? Biochem. J. 479, 273–288 (2022). · DOI
  30. Szymanska, E., Budick-Harmelin, N. & Miaczynska, M. Endosomal “sort” of signaling control: the role of ESCRT machinery in regulation of receptor-mediated signaling pathways. Semin. Cell Dev. Biol. 74, 11–20 (2018). · DOI
  31. White, M. F. & Kahn, C. R. Insulin action at a molecular level–100 years of progress. Mol. Metab. 52, 101304 (2021). · DOI
  32. Fagerholm, S., Ortegren, U., Karlsson, M., Ruishalme, I. & Stralfors, P. Rapid insulin-dependent endocytosis of the insulin receptor by caveolae in primary adipocytes. PLoS ONE 4, e5985 (2009). · DOI
  33. McClain, D. A. & Olefsky, J. M. Evidence for two independent pathways of insulin-receptor internalization in hepatocytes and hepatoma cells. Diabetes 37, 806–815 (1988). · DOI
  34. Couet, J., Li, S., Okamoto, T., Ikezu, T. & Lisanti, M. P. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J. Biol. Chem. 272, 6525–6533 (1997). · DOI
  35. Nystrom, F. H., Chen, H., Cong, L. N., Li, Y. & Quon, M. J. Caveolin-1 interacts with the insulin receptor and can differentially modulate insulin signaling in transfected Cos-7 cells and rat adipose cells. Mol. Endocrinol. 13, 2013–2024 (1999). · DOI
  36. Carpentier, J. L. et al. Two steps of insulin receptor internalization depend on different domains of the beta-subunit. J. Cell Biol. 122, 1243–1252 (1993). · DOI
  37. Ceresa, B. P., Kao, A. W., Santeler, S. R. & Pessin, J. E. Inhibition of clathrin-mediated endocytosis selectively attenuates specific insulin receptor signal transduction pathways. Mol. Cell Biol. 18, 3862–3870 (1998). · DOI
  38. Iraburu, M. J., Garner, T. & Montiel-Duarte, C. Revising endosomal trafficking under insulin receptor activation. Int. J. Mol. Sci. https://doi.org/10.3390/ijms22136978 (2021). · DOI
  39. Fan, J. Y. et al. Receptor-mediated endocytosis of insulin: role of microvilli, coated pits, and coated vesicles. Proc. Natl Acad. Sci. USA 79, 7788–7791 (1982). · DOI
  40. Cohen, A. W. et al. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am. J. Physiol. Cell Physiol. 285, C222–C235 (2003). · DOI
  41. Razani, B. et al. Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Mol. Cell Biol. 22, 2329–2344 (2002). · DOI
  42. Langin, D. Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome. Pharmacol. Res. 53, 482–491 (2006). · DOI
  43. Kim, C. A. et al. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli–Seip congenital lipodystrophy. J. Clin. Endocrinol. Metab. 93, 1129–1134 (2008). · DOI
  44. Mann, J. P. & Savage, D. B. What lipodystrophies teach us about the metabolic syndrome. J. Clin. Invest. 129, 4009–4021 (2019). · DOI
  45. Ansarullah et al. Inceptor counteracts insulin signalling in β-cells to control glycaemia. Nature 590, 326–331 (2021). · DOI
  46. Rosen, O. M., Herrera, R., Olowe, Y., Petruzzelli, L. M. & Cobb, M. H. Phosphorylation activates the insulin receptor tyrosine protein kinase. Proc. Natl Acad. Sci. USA 80, 3237–3240 (1983). · DOI
  47. Bevan, A. P. et al. Selective activation of the rat hepatic endosomal insulin receptor kinase. Role for the endosome in insulin signaling. J. Biol. Chem. 270, 10784–10791 (1995). · DOI
  48. Schenck, A. et al. The endosomal protein Appl1 mediates Akt substrate specificity and cell survival in vertebrate development. Cell 133, 486–497 (2008). · DOI
  49. Kalaidzidis, I. et al. APPL endosomes are not obligatory endocytic intermediates but act as stable cargo-sorting compartments. J. Cell Biol. 211, 123–144 (2015). · DOI
  50. Mitsuuchi, Y. et al. Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2. Oncogene 18, 4891–4898 (1999). · DOI
  51. Ryu, J. et al. APPL1 potentiates insulin sensitivity by facilitating the binding of IRS1/2 to the insulin receptor. Cell Rep. 7, 1227–1238 (2014). · DOI
  52. Tan, Y., You, H., Coffey, F. J., Wiest, D. L. & Testa, J. R. Appl1 is dispensable for Akt signaling in vivo and mouse T-cell development. Genesis 48, 531–539 (2010). · DOI
  53. Cheng, K. K. et al. APPL1 potentiates insulin-mediated inhibition of hepatic glucose production and alleviates diabetes via Akt activation in mice. Cell Metab. 9, 417–427 (2009). · DOI
  54. Alliouachene, S. et al. Inactivation of the class II PI3K-C2β potentiates insulin signaling and sensitivity. Cell Rep. 13, 1881–1894 (2015). · DOI
  55. Hunker, C. M. et al. Role of Rab5 in insulin receptor-mediated endocytosis and signaling. Arch. Biochem. Biophys. 449, 130–142 (2006). · DOI
  56. Seely, B. L. et al. Protein tyrosine phosphatase 1B interacts with the activated insulin receptor. Diabetes 45, 1379–1385 (1996). · DOI
  57. Byon, J. C., Kusari, A. B. & Kusari, J. Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction. Mol. Cell Biochem. 182, 101–108 (1998). · DOI
  58. Carpentier, J. L., Fehlmann, M., Van Obberghen, E., Gorden, P. & Orci, L. Insulin receptor internalization and recycling: mechanism and significance. Biochimie 67, 1143–1145 (1985). · DOI
  59. Gillingham, A. K. & Munro, S. The small G proteins of the Arf family and their regulators. Annu. Rev. Cell Dev. Biol. 23, 579–611 (2007). · DOI
  60. Rodiger, M. et al. Adiponectin release and insulin receptor targeting share trans-Golgi-dependent endosomal trafficking routes. Mol. Metab. 8, 167–179 (2018). · DOI
  61. Authier, F. & Desbuquois, B. Glucagon receptors. Cell Mol. Life Sci. 65, 1880–1899 (2008). · DOI
  62. Zeigerer, A. et al. Glucagon’s metabolic action in health and disease. Compr. Physiol. 11, 1759–1783 (2021). · DOI
  63. Merlen, C., Fabrega, S., Desbuquois, B., Unson, C. G. & Authier, F. Glucagon-mediated internalization of serine-phosphorylated glucagon receptor and Gsα in rat liver. FEBS Lett. 580, 5697–5704 (2006). · DOI
  64. Watanabe, J., Kanai, K. & Kanamura, S. Glucagon receptors in endothelial and Kupffer cells of mouse liver. J. Histochem. Cytochem. 36, 1081–1089 (1988). · DOI
  65. Krilov, L. et al. Dual mode of glucagon receptor internalization: role of PKCα, GRKs and β-arrestins. Exp. Cell Res. 317, 2981–2994 (2011). · DOI
  66. Authier, F., Janicot, M., Lederer, F. & Desbuquois, B. Fate of injected glucagon taken up by rat liver in vivo. Degradation of internalized ligand in the endosomal compartment. Biochem. J. 272, 703–712 (1990). · DOI
  67. Krilov, L., Nguyen, A., Miyazaki, T., Unson, C. G. & Bouscarel, B. Glucagon receptor recycling: role of carboxyl terminus, β-arrestins, and cytoskeleton. Am. J. Physiol. Cell Physiol. 295, C1230–C1237 (2008). · DOI
  68. Bomholt, A. B. et al. Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression. bioRxiv https://doi.org/10.1101/2021.12.21.473442 (2021). · DOI
  69. Van Der Sluijs, P. et al. The small GTP-binding protein rab4 is associated with early endosomes. Proc. Natl Acad. Sci. USA 88, 6313–6317 (1991). · DOI
  70. Perrin, L. et al. Rab4b controls an early endosome sorting event by interacting with the γ-subunit of the clathrin adaptor complex 1. J. Cell Sci. 126, 4950–4962 (2013).
  71. Kaur, S., Chen, Y. & Shenoy, S. K. Agonist-activated glucagon receptors are deubiquitinated at early endosomes by two distinct deubiquitinases to facilitate Rab4a-dependent recycling. J. Biol. Chem. 295, 16630–16642 (2020). · DOI
  72. Cegla, J. et al. RAMP2 influences glucagon receptor pharmacology via trafficking and signaling. Endocrinology 158, 2680–2693 (2017). · DOI
  73. McGlone, E. R. et al. Receptor activity-modifying protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling. Mol. Metab. 53, 101296 (2021). · DOI
  74. Zhu, L. et al. Hepatic β-arrestin 2 is essential for maintaining euglycemia. J. Clin. Invest. 127, 2941–2945 (2017). · DOI
  75. Wang, Y. et al. Glucagon is associated with NAFLD inflammatory progression in type 2 diabetes, not with NAFLD fibrotic progression. Eur. J. Gastroenterol. Hepatol. 33, e818–e823 (2021). · DOI
  76. Sorensen, H. et al. Glucagon receptor knockout mice display increased insulin sensitivity and impaired β-cell function. Diabetes 55, 3463–3469 (2006). · DOI
  77. Drucker, D. J. & Nauck, M. A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696–1705 (2006). · DOI · Paper page
  78. Campbell, J. E. Targeting the GIPR for obesity: to agonize or antagonize? Potential mechanisms. Mol. Metab. 46, 101139 (2021). · DOI · Paper page
  79. Morgan, L. M., Flatt, P. R. & Marks, V. Nutrient regulation of the enteroinsular axis and insulin secretion. Nutr. Res. Rev. 1, 79–97 (1988). · DOI
  80. Yamada, Y. & Seino, Y. Physiology of GIP–a lesson from GIP receptor knockout mice. Horm. Metab. Res. 36, 771–774 (2004). · DOI
  81. El, K. & Campbell, J. E. The role of GIP in α-cells and glucagon secretion. Peptides 125, 170213 (2020). · DOI
  82. Zhang, Q. et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab. 33, 833–844.e5 (2021). · DOI · Paper page
  83. Mohammad, S. et al. Gastric inhibitory peptide controls adipose insulin sensitivity via activation of cAMP-response element-binding protein and p110β isoform of phosphatidylinositol 3-kinase. J. Biol. Chem. 286, 43062–43070 (2011). · DOI · Paper page
  84. Mohammad, S. et al. A naturally occurring GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs GIP control of adipose insulin sensitivity. Mol. Cell Biol. 34, 3618–3629 (2014). · DOI · Paper page
  85. Gabe, M. B. N. et al. Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors. Biochem. Pharmacol. 150, 97–107 (2018). · DOI
  86. Abdullah, N., Beg, M., Soares, D., Dittman, J. S. & McGraw, T. E. Downregulation of a GPCR by β-arrestin2-mediated switch from an endosomal to a TGN recycling pathway. Cell Rep. 17, 2966–2978 (2016). · DOI
  87. Ismail, S. et al. Internalized receptor for glucose-dependent insulinotropic peptide stimulates adenylyl cyclase on early endosomes. Biochem. Pharmacol. 120, 33–45 (2016). · DOI
  88. Roussel, M., Mathieu, J. & Dalle, S. Molecular mechanisms redirecting the GLP-1 receptor signalling profile in pancreatic β-cells during type 2 diabetes. Horm. Mol. Biol. Clin. Investig. 26, 87–95 (2016). · DOI
  89. Pierce, K. L., Premont, R. T. & Lefkowitz, R. J. Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3, 639–650 (2002). · DOI
  90. Girada, S. B. et al. Gαs regulates glucagon-like peptide 1 receptor-mediated cyclic AMP generation at Rab5 endosomal compartment. Mol. Metab. 6, 1173–1185 (2017). · DOI
  91. Syme, C. A., Zhang, L. & Bisello, A. Caveolin-1 regulates cellular trafficking and function of the glucagon-like peptide 1 receptor. Mol. Endocrinol. 20, 3400–3411 (2006). · DOI
  92. Buenaventura, T. et al. A targeted RNAi screen identifies endocytic trafficking factors that control GLP-1 receptor signaling in pancreatic β-cells. Diabetes 67, 385–399 (2018). · DOI
  93. Li, D. T. et al. GLUT4 storage vesicles: specialized organelles for regulated trafficking. Yale J. Biol. Med. 92, 453–470 (2019).
  94. Gould, G. W., Brodsky, F. M. & Bryant, N. J. Building GLUT4 vesicles: CHC22 clathrin’s human touch. Trends Cell Biol. 30, 705–719 (2020). · DOI
  95. Batty, S. R. & Langlais, P. R. Microtubules in insulin action: what’s on the tube? Trends Endocrinol. Metab. 32, 776–789 (2021). · DOI
  96. Jaldin-Fincati, J. R., Pavarotti, M., Frendo-Cumbo, S., Bilan, P. J. & Klip, A. Update on GLUT4 vesicle traffic: a cornerstone of insulin action. Trends Endocrinol. Metab. 28, 597–611 (2017). · DOI
  97. Stockli, J., Fazakerley, D. J. & James, D. E. GLUT4 exocytosis. J. Cell Sci. 124, 4147–4159 (2011). · DOI
  98. Leto, D. & Saltiel, A. R. Regulation of glucose transport by insulin: traffic control of GLUT4. Nat. Rev. Mol. Cell Biol. 13, 383–396 (2012). · DOI · Paper page
  99. Foley, K., Boguslavsky, S. & Klip, A. Endocytosis, recycling, and regulated exocytosis of glucose transporter 4. Biochemistry 50, 3048–3061 (2011). · DOI
  100. Bogan, J. S. Regulation of glucose transporter translocation in health and diabetes. Annu. Rev. Biochem. 81, 507–532 (2012). · DOI · Paper page
  101. Zeigerer, A. et al. GLUT4 retention in adipocytes requires two intracellular insulin-regulated transport steps. Mol. Biol. Cell 13, 2421–2435 (2002). · DOI
  102. Volchuk, A. et al. Perturbation of dynamin II with an amphiphysin SH3 domain increases GLUT4 glucose transporters at the plasma membrane in 3T3-L1 adipocytes. Dynamin II participates in GLUT4 endocytosis. J. Biol. Chem. 273, 8169–8176 (1998). · DOI
  103. Nishimura, H., Zarnowski, M. J. & Simpson, I. A. Glucose transporter recycling in rat adipose cells. Effects of potassium depletion. J. Biol. Chem. 268, 19246–19253 (1993). · DOI
  104. Robinson, L. J., Pang, S., Harris, D. S., Heuser, J. & James, D. E. Translocation of the glucose transporter (GLUT4) to the cell surface in permeabilized 3T3-L1 adipocytes: effects of ATP insulin, and GTP gamma S and localization of GLUT4 to clathrin lattices. J. Cell Biol. 117, 1181–1196 (1992). · DOI
  105. Marsh, B. J., Alm, R. A., McIntosh, S. R. & James, D. E. Molecular regulation of GLUT-4 targeting in 3T3-L1 adipocytes. J. Cell Biol. 130, 1081–1091 (1995). · DOI
  106. Pan, X., Zaarur, N., Singh, M., Morin, P. & Kandror, K. V. Sortilin and retromer mediate retrograde transport of Glut4 in 3T3-L1 adipocytes. Mol. Biol. Cell 28, 1667–1675 (2017). · DOI · Paper page
  107. Yang, Z. et al. Functional characterization of retromer in GLUT4 storage vesicle formation and adipocyte differentiation. FASEB J. 30, 1037–1050 (2016). · DOI
  108. Blot, V. & McGraw, T. E. Molecular mechanisms controlling GLUT4 intracellular retention. Mol. Biol. Cell 19, 3477–3487 (2008). · DOI
  109. Foley, K. P. & Klip, A. Dynamic GLUT4 sorting through a syntaxin-6 compartment in muscle cells is derailed by insulin resistance-causing ceramide. Biol. Open 3, 314–325 (2014). · DOI
  110. Shewan, A. M. et al. GLUT4 recycles via a trans-Golgi network (TGN) subdomain enriched in syntaxins 6 and 16 but not TGN38: involvement of an acidic targeting motif. Mol. Biol. Cell 14, 973–986 (2003). · DOI
  111. Proctor, K. M., Miller, S. C., Bryant, N. J. & Gould, G. W. Syntaxin 16 controls the intracellular sequestration of GLUT4 in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 347, 433–438 (2006). · DOI
  112. Li, L. V. & Kandror, K. V. Golgi-localized, γ-ear-containing, Arf-binding protein adaptors mediate insulin-responsive trafficking of glucose transporter 4 in 3T3-L1 adipocytes. Mol. Endocrinol. 19, 2145–2153 (2005). · DOI
  113. Vollenweider, P. et al. The small guanosine triphosphate-binding protein Rab4 is involved in insulin-induced GLUT4 translocation and actin filament rearrangement in 3T3-L1 cells. Endocrinology 138, 4941–4949 (1997). · DOI
  114. Cormont, M. et al. Potential role of Rab4 in the regulation of subcellular localization of Glut4 in adipocytes. Mol. Cell Biol. 16, 6879–6886 (1996). · DOI
  115. Mari, M. et al. The Rab4 effector Rabip4 plays a role in the endocytotic trafficking of Glut 4 in 3T3-L1 adipocytes. J. Cell Sci. 119, 1297–1306 (2006). · DOI
  116. Lampson, M. A., Schmoranzer, J., Zeigerer, A., Simon, S. M. & McGraw, T. E. Insulin-regulated release from the endosomal recycling compartment is regulated by budding of specialized vesicles. Mol. Biol. Cell 12, 3489–3501 (2001). · DOI
  117. Hirshman, M. F., Goodyear, L. J., Wardzala, L. J., Horton, E. D. & Horton, E. S. Identification of an intracellular pool of glucose transporters from basal and insulin-stimulated rat skeletal muscle. J. Biol. Chem. 265, 987–991 (1990). · DOI
  118. Tanti, J. F., Gremeaux, T., Van Obberghen, E. & Le Marchand-Brustel, Y. Insulin receptor substrate 1 is phosphorylated by the serine kinase activity of phosphatidylinositol 3-kinase. Biochem. J. 304, 17–21 (1994). · DOI
  119. Bjornholm, M., Kawano, Y., Lehtihet, M. & Zierath, J. R. Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes 46, 524–527 (1997). · DOI
  120. Dannhauser, P. N. et al. CHC22 and CHC17 clathrins have distinct biochemical properties and display differential regulation and function. J. Biol. Chem. 292, 20834–20844 (2017). · DOI
  121. Camus, S. M. et al. CHC22 clathrin mediates traffic from early secretory compartments for human GLUT4 pathway biogenesis. J. Cell Biol. https://doi.org/10.1083/jcb.201812135 (2020). · DOI
  122. Maianu, L., Keller, S. R. & Garvey, W. T. Adipocytes exhibit abnormal subcellular distribution and translocation of vesicles containing glucose transporter 4 and insulin-regulated aminopeptidase in type 2 diabetes mellitus: implications regarding defects in vesicle trafficking. J. Clin. Endocrinol. Metab. 86, 5450–5456 (2001). · DOI
  123. Zierath, J. R. et al. Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia 39, 1180–1189 (1996). · DOI · Paper page
  124. Benninghoff, T. et al. The RabGAPs TBC1D1 and TBC1D4 control uptake of long-chain fatty acids into skeletal muscle via fatty acid transporter SLC27A4/FATP4. Diabetes 69, 2281–2293 (2020). · DOI
  125. Sano, H. et al. Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J. Biol. Chem. 278, 14599–14602 (2003). · DOI
  126. Mafakheri, S. et al. AKT and AMP-activated protein kinase regulate TBC1D1 through phosphorylation and its interaction with the cytosolic tail of insulin-regulated aminopeptidase IRAP. J. Biol. Chem. 293, 17853–17862 (2018). · DOI
  127. Sakamoto, K. & Holman, G. D. Emerging role for AS160/TBC1D4 and TBC1D1 in the regulation of GLUT4 traffic. Am. J. Physiol. Endocrinol. Metab. 295, E29–E37 (2008). · DOI · Paper page
  128. Hatakeyama, H., Morino, T., Ishii, T. & Kanzaki, M. Cooperative actions of Tbc1d1 and AS160/Tbc1d4 in GLUT4-trafficking activities. J. Biol. Chem. 294, 1161–1172 (2019). · DOI
  129. Dash, S. et al. A truncation mutation in TBC1D4 in a family with acanthosis nigricans and postprandial hyperinsulinemia. Proc. Natl Acad. Sci. USA 106, 9350–9355 (2009). · DOI
  130. Miinea, C. P. et al. AS160, the Akt substrate regulating GLUT4 translocation, has a functional Rab GTPase-activating protein domain. Biochem. J. 391, 87–93 (2005). · DOI · Paper page
  131. Roach, W. G., Chavez, J. A., Miinea, C. P. & Lienhard, G. E. Substrate specificity and effect on GLUT4 translocation of the Rab GTPase-activating protein Tbc1d1. Biochem. J. 403, 353–358 (2007). · DOI
  132. Stockli, J., Fazakerley, D. J., Coster, A. C., Holman, G. D. & James, D. E. Muscling in on GLUT4 kinetics. Commun. Integr. Biol. 3, 260–262 (2010). · DOI
  133. Fazakerley, D. J., Koumanov, F. & Holman, G. D. GLUT4 on the move. Biochem. J. 479, 445–462 (2022). · DOI
  134. Belman, J. P. et al. Acetylation of TUG protein promotes the accumulation of GLUT4 glucose transporters in an insulin-responsive intracellular compartment. J. Biol. Chem. 290, 4447–4463 (2015). · DOI
  135. Bogan, J. S. et al. Endoproteolytic cleavage of TUG protein regulates GLUT4 glucose transporter translocation. J. Biol. Chem. 287, 23932–23947 (2012). · DOI
  136. Habtemichael, E. N. et al. Usp25m protease regulates ubiquitin-like processing of TUG proteins to control GLUT4 glucose transporter translocation in adipocytes. J. Biol. Chem. 293, 10466–10486 (2018). · DOI
  137. Habtemichael, E. N. et al. Insulin-stimulated endoproteolytic TUG cleavage links energy expenditure with glucose uptake. Nat. Metab. 3, 378–393 (2021). · DOI
  138. Fischer, A. W. et al. The adaptor protein PID1 regulates receptor-dependent endocytosis of postprandial triglyceride-rich lipoproteins. Mol. Metab. 16, 88–99 (2018). · DOI
  139. Jedrychowski, M. P. et al. Proteomic analysis of GLUT4 storage vesicles reveals LRP1 to be an important vesicle component and target of insulin signaling. J. Biol. Chem. 285, 104–114 (2010). · DOI
  140. Fischer, A. W. et al. PID1 regulates insulin-dependent glucose uptake by controlling intracellular sorting of GLUT4-storage vesicles. Biochim. Biophys. Acta Mol. Basis Dis. 1865, 1592–1603 (2019). · DOI
  141. Goldstein, J. L. & Brown, M. S. The LDL receptor. Arterioscler. Thromb. Vasc. Biol. 29, 431–438 (2009). · DOI · Paper page
  142. Go, G. W. & Mani, A. Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. Yale J. Biol. Med. 85, 19–28 (2012).
  143. Mishra, S. K., Watkins, S. C. & Traub, L. M. The autosomal recessive hypercholesterolemia (ARH) protein interfaces directly with the clathrin-coat machinery. Proc. Natl Acad. Sci. USA 99, 16099–16104 (2002). · DOI · Paper page
  144. Wu, J. H. et al. The adaptor protein beta-arrestin2 enhances endocytosis of the low density lipoprotein receptor. J. Biol. Chem. 278, 44238–44245 (2003). · DOI
  145. Kim, J. et al. Beta-arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration. Circ. Res. 103, 70–79 (2008). · DOI
  146. Zhang, C., Hao, C., Shui, G. & Li, W. BLOS1 mediates kinesin switch during endosomal recycling of LDL receptor. Elife https://doi.org/10.7554/eLife.58069 (2020). · DOI
  147. Scott, I., Wang, L., Wu, K., Thapa, D. & Sack, M. N. GCN5L1/BLOS1 links acetylation, organelle remodeling, and metabolism. Trends Cell Biol. 28, 346–355 (2018). · DOI
  148. Vos, D. Y. & van de Sluis, B. Function of the endolysosomal network in cholesterol homeostasis and metabolic-associated fatty liver disease (MAFLD). Mol. Metab. 50, 101146 (2021). · DOI
  149. Zelcer, N., Hong, C., Boyadjian, R. & Tontonoz, P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 325, 100–104 (2009). · DOI · Paper page
  150. Poirier, S. & Mayer, G. The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des. Devel Ther. 7, 1135–1148 (2013).
  151. Goldstein, J. L., Anderson, R. G. W. & Brown, M. S. In Ciba Foundation Symposium 92–Membrane Recycling Ch. 5 (eds Evered, D. & Collins, G.M.) 77–95 (Pitman, 1982). · DOI
  152. Jang, H. D. et al. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9. Eur. Heart J. 41, 239–252 (2020). · DOI
  153. Ruscica, M. et al. Liver fat accumulation is associated with circulating PCSK9. Ann. Med. 48, 384–391 (2016). · DOI
  154. Krahmer, N. et al. Organellar proteomics and phospho-proteomics reveal subcellular reorganization in diet-induced hepatic steatosis. Dev. Cell 47, 205–221.e7 (2018). · DOI · Paper page
  155. Luiken, J., Nabben, M., Neumann, D. & Glatz, J. F. C. Understanding the distinct subcellular trafficking of CD36 and GLUT4 during the development of myocardial insulin resistance. Biochim. Biophys. Acta Mol. Basis Dis. 1866, 165775 (2020). · DOI
  156. Xue, B. et al. Effects of high fat feeding on adipose tissue gene expression in diabetic Goto-Kakizaki rats. Gene Regul. Syst. Bio 9, 15–26 (2015).
  157. Kita, Y. et al. Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. PLoS ONE 7, e43056 (2012). · DOI
  158. Gilleron, J. et al. Rab4b deficiency in T cells promotes adipose Treg/Th17 imbalance, adipose tissue dysfunction, and insulin resistance. Cell Rep. 25, 3329–3341.e25 (2018). · DOI
  159. Kaddai, V. et al. Involvement of TNF-α in abnormal adipocyte and muscle sortilin expression in obese mice and humans. Diabetologia 52, 932–940 (2009). · DOI
  160. Salani, B. et al. Caveolin-1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells. FASEB J. 26, 788–798 (2012). · DOI
  161. Salis, O., Bedir, A., Ozdemir, T., Okuyucu, A. & Alacam, H. The relationship between anticancer effect of metformin and the transcriptional regulation of certain genes (CHOP, CAV-1, HO-1, SGK-1 and Par-4) on MCF-7 cell line. Eur. Rev. Med. Pharmacol. Sci. 18, 1602–1609 (2014).
  162. Strong, A., Patel, K. & Rader, D. J. Sortilin and lipoprotein metabolism: making sense out of complexity. Curr. Opin. Lipidol. 25, 350–357 (2014). · DOI
  163. Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203–209 (2018). · DOI · Paper page
  164. Conlon, D. M. et al. Sortilin restricts secretion of apolipoprotein B-100 by hepatocytes under stressed but not basal conditions. J. Clin. Invest. https://doi.org/10.1172/JCI144334 (2022). · DOI · Paper page
  165. Kathiresan, S. et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 40, 189–197 (2008). · DOI · Paper page
  166. Conlon, D. M. Role of sortilin in lipid metabolism. Curr. Opin. Lipidol. 30, 198–204 (2019). · DOI
  167. Rabinowich, L. et al. Sortilin deficiency improves the metabolic phenotype and reduces hepatic steatosis of mice subjected to diet-induced obesity. J. Hepatol. 62, 175–181 (2015). · DOI
  168. Chen, C., Li, J., Matye, D. J., Wang, Y. & Li, T. Hepatocyte sortilin 1 knockout and treatment with a sortilin 1 inhibitor reduced plasma cholesterol in Western diet-fed mice. J. Lipid Res. 60, 539–549 (2019). · DOI · Paper page
  169. Wu, L. et al. Rab8a-AS160-MSS4 regulatory circuit controls lipid droplet fusion and growth. Dev. Cell 30, 378–393 (2014). · DOI
  170. Deus, C. M., Yambire, K. F., Oliveira, P. J. & Raimundo, N. Mitochondria-lysosome crosstalk: from physiology to neurodegeneration. Trends Mol. Med. 26, 71–88 (2020). · DOI
  171. Hsu, F. et al. Rab5 and Alsin regulate stress-activated cytoprotective signaling on mitochondria. Elife https://doi.org/10.7554/eLife.32282 (2018). · DOI
  172. Sugiura, A., McLelland, G. L., Fon, E. A. & McBride, H. M. A new pathway for mitochondrial quality control: mitochondrial-derived vesicles. EMBO J. 33, 2142–2156 (2014). · DOI · Paper page
  173. Shin, H. W. et al. An enzymatic cascade of Rab5 effectors regulates phosphoinositide turnover in the endocytic pathway. J. Cell Biol. 170, 607–618 (2005). · DOI
  174. Bilanges, B. et al. Vps34 PI 3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism. Nat. Commun. 8, 1804 (2017). · DOI
  175. Hamdi, A. et al. Erythroid cell mitochondria receive endosomal iron by a “kiss-and-run” mechanism. Biochim. Biophys. Acta 1863, 2859–2867 (2016). · DOI
  176. Wei, Z., Su, W., Lou, H., Duan, S. & Chen, G. Trafficking pathway between plasma membrane and mitochondria via clathrin-mediated endocytosis. J. Mol. Cell Biol. 10, 539–548 (2018). · DOI
  177. Hothersall, J. D., Brown, A. J., Dale, I. & Rawlins, P. Can residence time offer a useful strategy to target agonist drugs for sustained GPCR responses? Drug Discov. Today 21, 90–96 (2016). · DOI
  178. Jones, B. et al. Targeting GLP-1 receptor trafficking to improve agonist efficacy. Nat. Commun. 9, 1602 (2018). · DOI
  179. Pickford, P. et al. Signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide. Br. J. Pharmacol. 177, 3905–3923 (2020). · DOI
  180. Novikoff, A. et al. Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists. Mol. Metab. 49, 101181 (2021). · DOI
  181. Wu, Q. et al. Biased agonists with less glucagon-like peptide-1 receptor-mediated endocytosis prolong hypoglycaemic effects. Eur. J. Pharmacol. 907, 174203 (2021). · DOI
  182. Miaczynska, M. Effects of membrane trafficking on signaling by receptor tyrosine kinases. Cold Spring Harb. Perspect. Biol. 5, a009035 (2013). · DOI
  183. Calebiro, D. et al. Persistent cAMP-signals triggered by internalized G-protein-coupled receptors. PLoS Biol. 7, e1000172 (2009). · DOI
  184. Ahlqvist, E. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 6, 361–369 (2018). · DOI · Paper page
  185. Zaharia, O. P. et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol. 7, 684–694 (2019). · DOI · Paper page
  186. Picatoste, B. et al. Defective insulin-stimulated GLUT4 translocation in brown adipocytes induces systemic glucose homeostasis dysregulation independent of thermogenesis in female mice. Mol. Metab. 53, 101305 (2021). · DOI
  187. Meier, J. J., Veldhuis, J. D. & Butler, P. C. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes 54, 1649–1656 (2005). · DOI · Paper page
  188. Farris, W. et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc. Natl Acad. Sci. USA 100, 4162–4167 (2003). · DOI
  189. Abdul-Hay, S. O. et al. Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance. PLoS ONE 6, e20818 (2011). · DOI
  190. Steneberg, P. et al. The type 2 diabetes-associated gene Ide is required for insulin secretion and suppression of α-synuclein levels in β-cells. Diabetes 62, 2004–2014 (2013). · DOI
  191. Villasenor, R., Lampe, J., Schwaninger, M. & Collin, L. Intracellular transport and regulation of transcytosis across the blood-brain barrier. Cell Mol. Life Sci. 76, 1081–1092 (2019). · DOI
  192. Nikolakopoulou, A. M. et al. Endothelial LRP1 protects against neurodegeneration by blocking cyclophilin A. J. Exp. Med. https://doi.org/10.1084/jem.20202207 (2021). · DOI
  193. Zhou, A. L. et al. Apolipoprotein A-I crosses the blood-brain barrier through clathrin-independent and cholesterol-mediated endocytosis. J. Pharmacol. Exp. Ther. 369, 481–488 (2019). · DOI
  194. Duquenne, M. et al. Leptin brain entry via a tanycytic LepR-EGFR shuttle controls lipid metabolism and pancreas function. Nat. Metab. 3, 1071–1090 (2021). · DOI
  195. Kaksonen, M. & Roux, A. Mechanisms of clathrin-mediated endocytosis. Nat. Rev. Mol. Cell Biol. 19, 313–326 (2018). · DOI · Paper page
  196. Chen, Z. & Schmid, S. L. Evolving models for assembling and shaping clathrin-coated pits. J. Cell Biol. https://doi.org/10.1083/jcb.202005126 (2020). · DOI
  197. Sorkin, A. Cargo recognition during clathrin-mediated endocytosis: a team effort. Curr. Opin. Cell Biol. 16, 392–399 (2004). · DOI
  198. Kelly, B. T. et al. A structural explanation for the binding of endocytic dileucine motifs by the AP2 complex. Nature 456, 976–979 (2008). · DOI
  199. Lamaze, C., Tardif, N., Dewulf, M., Vassilopoulos, S. & Blouin, C. M. The caveolae dress code: structure and signaling. Curr. Opin. Cell Biol. 47, 117–125 (2017). · DOI

Cited by

Sorted by citations

Metadata

Authors
Gilleron, J., & Zeigerer, A.
ORCID
Zeigerer, Anja
Venue
Nature Reviews Endocrinology
Publisher
Springer Science and Business Media LLC
Published
2022-10-10
Volume
19
Issue
1
Pages
28-45
ISSN
  • 1759-5029
  • 1759-5037
DOI
10.1038/s41574-022-00737-9
Cited by
57
References
25
Language
en
Update notices
correction (2022-10-31)
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review